Yunkang Group Limited

Equities

2325

KYG9889T1067

Healthcare Facilities & Services

Market Closed - Hong Kong S.E. Other stock markets 04:09:05 2024-06-07 EDT			5-day change	1st Jan Change
10.92 ^HKD	-0.18%		0.00%	-11.22%

05-13	Yunkang Group Sees Potential in Outsourcing Lab Testing Services for China's Public Hospitals	MT
04-05	Everbest Machinery Industry to Set Up 30 Million Yuan Joint Venture	MT

Yunkang Group Limited Provides Earnings Guidance for the Six Months Ended June 30, 2022

July 12, 2022 at 10:00 am

Yunkang Group Limited provided earnings guidance for the six months ended June 30, 2022. For the six months, the company expected to record a net profit approximately in the range of RMB 226 million to RMB 242 million for the interim results.

Latest news about Yunkang Group Limited

Yunkang Group Sees Potential in Outsourcing Lab Testing Services for China's Public Hospitals	05-13	MT
Everbest Machinery Industry to Set Up 30 Million Yuan Joint Venture	04-05	MT
Yunkang Swings to Loss in 2023; Recommends Dividend	03-26	MT
Yunkang Group Limited Proposes Final Cash Dividend for the Financial Year End 31 December 2023	03-25	CI
Yunkang Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	03-25	CI
Yunkang Group Expects a Loss of Up to 130 Million Yuan for Full Year 2023	03-06	MT
Yunkang Group Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023	03-05	CI
Yunkang Group's H1 Attributable Profit Plunges on Lower Revenue	23-08-31	MT
Yunkang Group Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
Yunkang Group Limited Announces Director Changes	23-08-30	CI
Yunkang's Profit to Drop Up to 83% in H1	23-08-14	MT
Yunkang Group Limited Approves Final Dividend for the Year Ended December 31, 2022, Payable on August 25, 2023	23-08-10	CI
Yunkang Group Limited Approves Final Dividend for the Year Ended December 31, 2022	23-06-28	CI
Alibaba Names Successors to Chairman & CEO	23-06-20	MT
Certain Ordinary Shares of Yunkang Group Limited are subject to a Lock-Up Agreement Ending on 17-MAY-2023.	23-05-16	CI
Over 200,000 Firms Want to Test Alibaba's AI Chatbot	23-04-28	MT
Yunkang Group Limited Declares Final Dividend for the Year Ended 31 December 2022	23-03-30	CI
Yunkang Group Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Disillusioned at home, super-rich Chinese set their sights on Singapore	23-01-30	RE
Yunkang Group Limited(SEHK:2325) added to S&P Global BMI Index	22-12-19	CI
Certain Ordinary Shares of Yunkang Group Limited are subject to a Lock-Up Agreement Ending on 17-NOV-2022.	22-11-16	CI
Yunkang's H1 Net Profit Grows 50% to $34.8 Million	22-08-12	MT
Yunkang Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2022	22-08-12	CI
Yunkang Group Limited Declares an Interim Dividend for the Six Months Ended June 30, 2022, Will Be Paid Before September 30, 2022	22-08-11	CI
Yunkang Group Limited Announces Executive Changes	22-08-11	CI

Chart Yunkang Group Limited

Duration

Period

More charts

Company Profile

Yunkang Group Ltd is a China-based Company mainly engaged in the provision of diagnosis testing services. The Company operates three segments. Diagnosis Testing segment provides diagnosis testing to hospital and non-medical clients, mainly including routine diagnostic testing, routine pathological examination, infectious disease diagnostic testing, genetic disease diagnostic testing and early cancer detection. Hospital Management Business segment provides management services for the community clinics. Research & Development Institution segment is engaged in the research and development of testing kits. The Company primarily provides services for hospitals and other medical institutions, and commercial entities such as financial institutions and insurance companies.

Sector

Healthcare Facilities & Services

More about the company

Income Statement Evolution

More financial data

Ratings for Yunkang Group Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

10.13 CNY

Average target price

12.93 CNY

Spread / Average Target

+27.63%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
YUNKANG GROUP LIMITED	-11.22%	840M
SONIC HEALTHCARE LIMITED	-22.13%	7.9B
RADNET, INC.	+76.16%	4.53B
DR. LAL PATHLABS LIMITED	+8.00%	2.78B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-50.41%	1.99B
NEOGENOMICS, INC.	-19.59%	1.66B
FLEURY S.A.	-20.07%	1.49B
METROPOLIS HEALTHCARE LIMITED	+19.31%	1.23B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-45.78%	1.1B
VIJAYA DIAGNOSTIC CENTRE LIMITED	+20.25%	996M

Medical & Diagnostic Laboratories